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glycaemic and weight-loss outcomes  
of graded doses of canagliflozin in type 2 
diabetes — a real-world study
ABSTrACT
Background. Costs are the most important cause 
of therapeutic non-compliance. half canagliflozin 
(CANA)–300 tablet has lowest cost/mg among all CANA 
preparations; data are unavailable on efficacy of half 
CANA-300. This study evaluated weight loss and gly-
caemic outcomes of 100 mg versus 150 mg versus 
300 mg of canagliflozin as part of standard therapy. 
Methods. Data, retrospectively captured from medical 
records of two centres in Delhi for patients > 35 years 
with type-2 diabetes (T2DM), and on canagliflozin, 
having > 6 months follow-up, were analysed. Patients 
were in 3-groups depending on canagliflozin dosage: 
Group 1 on canagliflozin 100 mg/day (1 tablet CANA- 
-100), Group-2 on canagliflozin 150 mg/day (half tablet 
CANA-300), and Group 3 on canagliflozin 300 mg/day 
(1 tablet CANA-300). Primary endpoints were glycaemic 
efficacy and weight-loss. 
results. From 3,569 records evaluated, 1,232 people 
with T2DM on canagliflozin were screened; data 
from 528 individuals analysed (257, 138 and 133 in 
groups: 1, 2 and 3 respectively). People in all three 
groups were comparable with regards to sex, T2DM 
duration, glycated haemoglobin (hbA1c), haemoglo-
bin, creatinine, lipids, albuminuria and medications. 
group-2 patients were youngest and had highest 
BMI. Following 6-months, both absolute and percent 
weight-loss was significantly higher in Group-2 (–3.5 kg 
[–6.60–0.00]; –3.62%), followed by group-3 (–3.0 kg 
[–5.3 to –0.8]; –3.33%), and lowest in group-1 (–1.05 kg 
[–2.85 to –0.17]; –1.31%) (P = 0.002 and 0.014, res-
pectively). Glycaemic efficacy was comparable among 
groups. 
Conclusion. half CANA-300 tablet has comparable 
glycaemic efficacy and weight-loss compared to single 
CANA-300 tablet, but superior weight-loss compared 
to CANA-100. (Clin Diabetol 2020; 9; 6: 442–453)
Key words: obesity canagliflozin, weight loss, 
diabetes reversal, euglycaemia, type 2 diabetes,  
cost analysis
Introduction
Diabetes and obesity, or diabesity, has become 
a global pandemic. Recent studies have suggested 
an alarming burden of diabetes and obesity in the 
Indian population. India currently has an overall 9% 
and 14–18% prevalence of diabetes and prediabetes, 
respectively [1, 2]. Indians are metabolically challenged, 
as is evidenced by nearly two decades earlier onset 
of diabetes coupled with one of the highest global 
annual rates of prediabetes progression to diabetes 
(14.0–18.0%, 11.0%, 6.0% and 2.5% per annum in 
India, China, Finland and USA, respectively) [3]. The 
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problem is especially acute in urban areas. The CARRS 
study, a population screening of 5,365 individuals 
from New Delhi, revealed a very high prevalence of 
prediabetes/diabetes of 72.7% [4]. Two studies from 
New Delhi reported very high rates of obesity in the 
general population (71.50% and 69.29% in a cohort of 
1,473 and 5,336 patients, respectively) [5, 6]. Hence, it 
is the high prevalence of obesity which is driving this 
diabetes epidemic, especially in the urban areas.
Recent studies have demonstrated the importance 
of weight loss in not only ensuring better glycaemic 
control in type 2 diabetes mellitus (T2DM), but also in 
diabetes remission [7]. Sodium-glucose co-transport-
er-2 (SGLT2) inhibitors have become popular agents for 
managing diabetes especially in the setting of diabesity. 
This is due to their good glycaemic efficacy, glycaemic 
durability, beneficial impact on cardiovascular out-
comes, low risk of hypoglycaemia, along with their 
mild weight-loss properties [8]. 
There are currently four SGLT2 inhibitors available 
for clinical practice in India: canagliflozin, dapagliflozin, 
empagliflozin and remogliflozin. In terms of selectivity 
for the inhibition of SGLT2, SGLT1 transporter, empa-
gliflozin, is the most selective, whereas canagliflozin is 
the least selective [8]. Hence canagliflozin is believed 
to have some additional therapeutic potential in view 
of its inhibiting SGLT1 transporters present in the 
intestines [9]. No significant impact of canagliflozin 
on SGLT1 transporter in heart and kidneys has been 
documented [10]. The intestinal SGLT1 transporter 
inhibition by canagliflozin is believed to result in an 
additional post–prandial glucose reduction, which is 
not seen with other SGLT2 inhibitors [10]. 
One of the major limitations with long-term use of 
SGLT2 inhibitors in clinical practice, is the significantly 
increased monthly costs of treatment. Since most of 
the healthcare expenditure is out of pocket in India, 
increased monthly treatment costs have been linked 
to poor medication compliance, resulting in impaired 
glycaemic control [11, 12]. Canagliflozin is currently 
available in 100 mg and 300 mg tablets for clinical use 
in India, costing INR 54.5 (INR 0.55/mg; INR 1,635 per 
month) and INR 120 (INR 0.4/mg; INR 3,600 per month) 
per tablet, respectively [13, 14]. Treatments costs for 
sulfonylurea glipizide 5 mg, metformin sustained 
release preparation 1 g, and pioglitazone 15 mg are: 
INR 0.53 per tablet (monthly cost INR 63.6 for 20 mg 
therapy per day), INR 3 per tablet (monthly cost INR 180 
for 2 g therapy per day) and INR 2 per tablet (monthly 
cost INR 120 for 30 mg therapy per day), respectively, 
highlighting nearly 10–60–times increased cost burden 
with SGLT2 inhibitor use in India [15]. The cost per unit 
of human regular insulin, human neutral protamine 
Hagedorn (NPH) insulin, lispro insulin, aspart insulin 
and glargine insulin is INR 0.96, 0.96, 2.26 and 2.19, 
respectively, when used in the form of cartridges for 
pen fill [16–19]. The monthly cost of therapy of above 
4 insulins when taken at doses of 20U/d would be 
INR 580, 580, 1,356 and 1,314 respectively [16–19]. 
Hence monthly costs of human insulin analogous 
(both short- and long-acting) is almost similar to that 
of SGLT2 inhibitors.
From costing point of view, half tablet of canagli-
flozin 300 mg (CANA-300) would provide 150 mg of 
canagliflozin at INR 60, which would be much more 
cost effective than taking 1.5 tablets of canagliflozin 
100 mg (CANA-100) tablet at INR 81.75. However, no 
data are available on the glycaemic and weight-loss 
properties of half tablet of CANA-300 taken once 
a day as compared to 1 tablet of CANA-100 per day 
and 1 tablet of CANA-300 per day in clinical practice. 
Half CANA-300 tablet has the lowest cost per mg as 
well as the lowest monthly cost of therapy among all 
the different doses of canagliflozin available for clinical 
use. Hence, this study aimed to evaluate the glycaemic 
efficacy and weight loss properties of graded doses 
of canagliflozin (100 mg, 150 mg, 300 mg), as a part 
of multi–drug therapy for managing type-2 diabetes 
in India.
Methods
Data were retrospectively captured from the elec-
tronic medical record (EMR) database of two different 
centres in New Delhi. Patients with T2DM, aged > 35 
years and on canagliflozin were considered for the 
study. T2DM onset in Indians is nearly 2 decades earlier 
than the western world, and the peak age of T2DM 
onset in Indians is in 30s and 40s [1, 20]. People > 35 
years–age were considered for this study to rule out 
those who were likely to have latent onset autoimmune 
diabetes of adults and late onset T1DM [1, 20]. 
Patients with associated severe chronic co-morbid 
states like chronic liver disease (Child’s B or C), renal 
disease (glomerular filtration rate < 60 mL/min as cal-
culated by CKD–EPI formula), cardiac disease (including 
coronary artery disease and heart failure), malignancies, 
active infection (tuberculosis, HIV, viral hepatitis), post 
organ transplant, patients on psychiatry medications, 
and those with chronic autoimmune disorders (lupus, 
scleroderma), were excluded. Also, patients with his-
tory of hospital admission in the last 6 months were 
excluded [6]. Patients with prior use of SGLT2 inhibitors 
were excluded. Incomplete records were excluded from 
the analysis. Details of other medications being used 
as per standard care were noted [6]. Patients on any 
other medications which can cause weight loss apart 
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from the medications considered in this study (cana-
gliflozin, metformin, glucagon like peptide 1 receptor 
agonists and orlistat) were excluded. Patients with at 
least 6 months follow-up data available were included 
in the study. The duration of this study was from Janu-
ary 2018 to February 2019. The entire flow of patient 
recruitment has been elaborated in Figure 1.
Patients were put into one of three groups de-
pending on their canagliflozin dose: Group 1 were 
on canagliflozin 100 mg/day (1 tablet of CANA-100), 
Group 2 were on canagliflozin 150 mg/day (half tab-
let of CANA-300), and Group 3 were on canagliflozin 
300 mg/day (1 tablet of CANA-300).
Patients in Group-2 (canagliflozin 150 mg/d) were 
given a demonstration how to split the CANA-300 
tablet. CANA-300 tablet is relatively a big tablet mak-
ing splitting easier. Using preferably a pill-cutter, the 
patients were shown how to cut the CANA-300 tablet 
(Fig. 2A) into 2 halves (Fig. 2B). In case a pill-cutter 
was not available, the patients were explained that 
Figure 2. A — appearance of an intact canagliflozin 300 mg tablet; B — appearance of split canagliflozin 300 mg tablet; 
C — storage of one-half of the split canagliflozin 300 mg tablet of use on the subsequent day
Figure 1. Flowchart of study protocol and flow of patients. GFR — glomerular filtration rate
STUDY POPULATION: 3569 electronic medical records (EMR) between January 2018 and February 2019 were screened
INCLUSION CRITERIA: Age > 35 years 
1232 patients with type 2 diabetes (T2DM) on canagliozin were considered
EXCLUSION CRITERIA: coronary artery disease (n = 116); 
chronic kidney disease (GFR < 60 mL/min) (n = 38); 
chronic lung disease (n = 69); hospital admission in the 
last 6 months (n = 110); autoimmune disorders (34); 
psychiatric problems on antipsychotic medications (38); 
chronic infections (n = 11); organ transplant (n = 4); 
follow–up duration less than 6 months (n = 153) 
Patients fullling all inclusion and exclusion criteria (n = 659)
Incomplete records/missing data (n = 131) 
Data from 528 patients for whom the complete 6 months follow up 
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a small kitchen knife can also be used to cut the tablet 
into 2 equal halves. The patients were asked to keep 
one of the halves in the tablet package carefully to be 
used the next day (Fig. 2C). They were reassured that 
sometimes the halves may not be exactly from the mid-
dle, but since the patient himself/herself will only be 
taking the other half of the tablet the subsequent day, 
it would average out and result in an overall intake of 
15 CANA-300 tablets over a period of 30 days.
Data for the following variables were collected 
at baseline and after 6 months follow-up (height, 
weight, fasting glucose, 2-hour post prandial glucose 
and HbA1c). Additionally, data were collected on 
haemoglobin, renal function status (creatinine), lipid-
parameters (low-density lipoprotein cholesterol (LDL-C) 
and triglycerides) and spot urine albumin creatinine 
ratio (ACR) as a measure of microvascular complication. 
Information was noted with regards to occurrence of 
different adverse drug reactions, specifically, hypogly-
caemia, genital infections, complicated upper urinary 
tract infections, fractures, euglycaemic ketosis and any 
other event reported by the patients.
Statistical analysis
Data analysis was done using the Statistical Pack-
age for Social Sciences (SPSS) version 20.0 (IBM, USA). 
Kolmogrov-Smirnov test was used to check the normal-
ity of the variable distribution. Normally distributed 
variables were expressed as mean ± standard deviation. 
Skewed variables were expressed as median (25th–75th 
percentile). ANOVA was used for comparing three or 
more study groups. Chi-square test was used for cat-
egorical variables. An a priori alpha of P < 0.05 was 
considered statistically significant.
Results
A total of 3,569 medical records were screened 
between January 2018 and February 2019, of which 
1,232 patients with T2DM were on canagliflozin. Data 
from 528 patients, who fulfilled all inclusion criteria 
and for whom at least 6-month follow-up data were 
available, were analysed. Out of the 528 patients, 257 
patients were on canagliflozin 100 mg/day (Group 1; 1 
tablet of CANA-100), 138 were on canagliflozin 150 mg/ 
/day (Group 2; half tablet of CANA-300) and 133 were 
on canagliflozin 300 mg/day (Group 3: 1 tablet of CANA-
-300). Demographic details, anthropometric, glycaemic, 
metabolic and medication profiles of the patients in the 
three groups have been elaborated in Table 1.
The patients in all three groups were comparable 
with regards to sex distribution, duration of T2DM, 
baseline HbA1c, haemoglobin, renal function (creati-
nine), lipid parameters and microvasculature damage 
(ACR), as per a direct ANOVA of the 3 groups (Table 1) 
as well as by a post-hoc pair wise analysis between 
each of the groups (Tables 2–4). The groups were also 
comparable with regards to use of all the other different 
anti-diabetes medications (metformin, sulfonylureas, 
dipeptidyl-peptidase-4 inhibitors, alpha glucosidase 
inhibitors, pioglitazone, glucagon like peptide-1 re-
ceptor agonists and insulins; as per a direct ANOVA 
of the 3 groups (Table 1) as well as by a post-hoc pair 
wise analysis between each of the groups (Tables 2–4). 
However, the patients in Group 2 were significantly 
younger as compared to patients in Groups 1 and 3 
(Tables 1–4). Additionally, BMI was significantly higher 
in patients in Group 2 as compared to Groups 1 and 3 
(Tables 1–4). Patients in Group-3 had significantly 
higher systolic and diastolic blood pressure (Table 3). 
Patients in Group-2 had a significantly higher diastolic 
blood pressure, but comparable systolic blood pressure 
as compared to Group-1 (Table 4).
Following 6 months of treatment, the absolute 
weight loss was highest in patients receiving canagli-
flozin 150 mg/day (Group 2; –3.5 kg [–6.60 to 0.00]) 
as compared to those receiving 100 mg/day (Group 1; 
–1.05 kg [–2.85 to –0.17]) and 300 mg/day (Group 3; 
–3.0 kg [–5.3 to –0.8]), which was statistically sig-
nificant (P = 0.002) (Table 1). The percent weight loss 
after 6 months of therapy (which is not effected by the 
higher baseline BMI) was also significantly higher in 
Group 2 (–3.62%) as compared to –3.33% and –1.31% 
in Groups 3 and Group 1 respectively, which was 
statistically significant (P = 0.014) (Table 1). Post-hoc 
analysis between each of the 3 groups re-confirmed 
this observation. A significantly higher absolute and 
percent weight loss among patients in Group-3 vs 
Group-1 (Table 3), Group-2 vs Group-1 (Table 4) with 
comparable absolute and percent weight loss among 
patients in Group-3 vs Group-2 (Table 2) highlights 
the superiority of canagliflozin 150 mg/day and 300 
mg/day over canagliflozin 100 mg/day with regards 
to weight loss.
In terms of glycaemic efficacy, the fall in HbA1c 
after 6 months of therapy, and the final HbA1c were 
not statistically different among the three groups 
(P = 0.083) (Table 1). Post-hoc analysis between each of 
the 3 groups re-confirmed this observation (Tables 2–4). 
The baseline HbA1c, the fall in HbA1c after 6 months 
of therapy and the final HbA1c were comparable when 
Group-3 was compared to Group-1 (Table 3), Group-2 
was compared to Group-1 (Table 4), and when Group-3 
was compared to Group-2 (Table 2) Groups 2 and 3 
were significantly different only with regards to age 
and in their baseline BMI (Table 2), hence a separate, 
post-hoc analysis of the study outcomes was done 
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for patients receiving canagliflozin 100 mg/day versus 
those receiving canagliflozin 150 mg/day or 300 mg/ 
/day (Table 5). 
Patients in the post-hoc analysis group (receiving 
canagliflozin 150 mg/day or 300 mg/day) were signifi-
cantly younger, had significantly higher baseline BMI, 
and had more severe hypertension, but were com-
parable with regards to use of all the other different 
anti-diabetes medications (metformin, sulfonylureas, 
dipeptidyl-peptidase-4 inhibitors, alpha glucosidase 
Table 1. Baseline demographics, treatment parameters and outcomes after 6 months of follow-up in patients receiving 
different graded doses of canagliflozin













Age, years 54.26 ± 10.58 45.31 ± 13.86 54.62 ± 10.08 < 0.001
Sex, male:female 139:118 78:61 71:62 0.891
Duration of diagnosis, years (range)* 4.5 (2.0–8.0) 4.0 (2.0–5.0) 4.0 (2.07–7.0) 0.275
BMI at baseline, kg/m2 27.96 ± 5.29 34.95 ± 5.76 32.92 ± 5.78 < 0.001
SBP, mm Hg 131.12 ± 19.70 134.92 ± 21.31 135.89 ± 19.42 0.057
DBP, mm Hg 79.19 ± 10.32 84.05 ± 10.61 82.25 ± 10.41 < 0.001
Weight, kg (range) † 72.95 (65.08–82.38) 93.9 (80.03–105.98) 84.6 (76.6–95.51) < 0.001
Absolute weight loss at 6 months, kg (range)† –1.05 (–2.85 to –0.17) –3.5 (–6.60 to 0.00) –3.0 (–5.3 to –0.81) 0.002
Percent weight loss at 6 months, % (range)† –1.31 (–3.28 to –0.22) –3.62 (–6.64 to 0.00) –3.33 (–6.00 to –0.99) 0.014
HbA1c, % (range) 8.1 (7.0–9.6) 8.1 (6.8–9.2) 8.8 (7.5–9.6) 0.153
HbA1c, mmol/mol (range)
† 65 (53–81) 65 (51–77) 73 (58–81)
HbA1c at 6 months, % (range) 7.70 (6.4–8.6) 7.0 (6.1–8.0) 7.2 (6.1–8.4) 0.303
HbA1c at 6 months, mmol/mol (range)
† 61 (46–70) 53 (43–64) 55 (43–68)
D HbA1c, % (range)
† –0.75 (–2.25 to 0.15) –0.90 (–1.83 to –0.05) –0.95 (–1.92 to –0.38) 0.833
HbA1c < 5.7% at 6 months, n (%) 6 (2.33%) 14 (10.14%) 6 (4.51%) 0.119
Creatinine, µmol/L 78.68 ± 20.33 69.84 ± 0.22.10 78.68 ± 30.94 0.159
Haemoglobin, gm/dL 12.08 ± 1.91 3.23 ± 1.99 12.51 ± 2.22
LDL-C, mmol/L† (range) 2.56 (1.74–3.42) 2.85 (2.01–3.94) 2.46 (2.06–3.45) 0.070
Triglycerides, mmol/L† (range) 1.93 (1.30–2.94) 1.81 (1.46–2.59) 2.31 (1.38–3.27) 0.339
Hypothyroidism, n (%) 26 (10.12%) 30 (21.74%) 11 (8.27%) 0.347
Metformin, n (%) 229 (89.11%) 128 (92.75%) 127 (95.49%) 0.097
GLP1a, n (%) 28 (10.89%) 25 (18.12%) 14 (10.53%) 0.089
DPP4i, n (%) 195 (75.88%) 98 (71.01%) 102 (76.69%) 0.415
Orlistat, n (%) 45 (17.51%) 30 (21.74%) 27 (20.30%) 0.587
Pioglitazone, n (%) 112 (43.58%) 49 (35.51%) 50 (37.59%) 0.223
Alpha-glucosidase inhibitors, n (%) 29 (11.28%) 21 (15.22%) 24 (18.05%) 0.179
Sulfonylureas, n (%) 219 (85.21%) 108 (78.26%) 111 (83.46%) 0.163
Basal insulin, n (%) 50 (19.46%) 28 (20.29%) 37 (27.82%) 0.148
Short acting insulin, n (%) 28 (10.89%) 20 (14.49%) 22 (16.54%) 0.273
ACR, mg/gm (range) 64.12 (32.42–187.14) 63.11 (32.24–212.13) 72.11 (16.14–331.43) 0.195
Severe hypoglycaemia, n 2 1 2 0.743
Non-severe hypoglycaemia, n 15 11 12 0.476
Genital infections, n 10 5 7 0.725
Normality of the variable distribution calculated using Kolmogorov-Smirov test; all normally distributed variables expressed as mean ± standard devia-
tion; discreet variables have been expressed as absolute numbers and percentages; P < 0.05 considered statistically significant. ANOVA was used for 
analysis. *As reported by the patient. †all non-normally distributed variables expressed as median (25th–75th percentile). D HbA1c — difference in glycated 
haemoglobin; ACR — spot urine albumin creatinine ratio; BMI — body mass index; DBP — diastolic blood pressure; DPP4i — dipeptidyl peptidase 4 inhibi-
tor; GLP1a — glucagon like peptide receptor-1 antagonists; HbA1c — glycated haemoglobin; LDL-C — low density lipoprotein cholesterol; SBP — systolic 
blood pressure
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inhibitors, pioglitazone, glucagon like peptide-1 recep-
tor agonists and insulins) (Table 5). Both absolute and 
percent weight loss was significantly higher among 
patients in the post-hoc analysis group (canagliflozin 
150 or 300 mg/day) as compared to those receiving 
100 mg/day (Table 5). Both basal and final HbA1c after 
6 months of therapy were comparable among the 
groups (Table 5). A greater percent of patients in the 
post-hoc analysis group (canagliflozin 150 or 300 mg/ 
/day) achieved HbA1c < 5.7% as compared to those on 
canagliflozin 100 mg/day but not statistically significant 
(20 vs 6; P = 0.428) (Table 5). 
There were five reports (0.009%) of severe hypogly-
caemia, necessitating a visit to the hospital emergency 
department, 38 (7.20%) reports of mild self-limiting 
hypoglycaemia, 22 reports (4.17%) of mild lower 
Table 2. Baseline clinical and treatment parameters and outcomes after 6 months of follow-up in patients receiving 
canagliflozin 150 mg per day as compared to those receiving 300 mg per day









Age (years) 45.31 ± 13.86 54.62 ± 10.08 0.001
Sex (Male:Female) 78:61 71: 62 0.651
Duration of diagnosis (years)* 4.0 [2.0–5.0] 4.0 [2.07–7.0] 0.163
BMI [kg/m2] 34.95 ± 5.76 32.92 ± 5.78 0.005
SBP [mm Hg] 134.92 ± 21.3 135.89 ± 19.4 0.707
DBP [mm Hg] 84.05 ± 10.61 82.25 ± 10.4 0.181
Weight [kg]† 93.9 [80.03 – 105.98] 84.6 [76.6–95.5] 0.001
Weight loss [kg]† –3.5 [–6.60–0.00] –3.0 [–5.3 to –0.8] 0.813
Percent weight loss at 6 months (%)† –3.62 [–6.64–0.00] –3.33 [–6.00 to –0.99] 0.734
HbA1c (%) 8.1 [6.8–9.2] 8.8 [7.5–9.6] 0.117
[mmol/mol]† 65 [51–77] 73 [58–81] 0.335
HbA1c at 6 months (%) 7.0 [6.1–8.0] 7.2 [6.1–8.4]
[mmol/mol]† 53 [43– 64] 55 [43–68]
D HbA1c (%)
† –0.90 [–1.8 to –0.05] –0.95 [–1.92 to –0.38] 0.589
HbA1c < 5.7% at 6 months 14 (10.14%) 6 (4.5%) 0.066
Creatinine [µmol/L] 69.84 ± 0.22.10 78.68 ± 30.94 0.113
Haemoglobin [gm/dL] 13.23 ± 1.99 12.51 ± 2.22 0.166
LDL-C [mmol/L]† 2.85 [2.01–3.94] 2.46 [2.06–3.45] 0.315
Triglycerides [mmol/L]† 1.81 [1.46–2.59] 2.31 [1.38–3.27] 0.054
Hypothyroidism 30 (21.73%) 11 (8.27%) 0.246
Metformin 128 (92.75%) 127 (95.48%) 0.247
GLP1a 25 (18.11%) 14 (10.52%) 0.079
DPP4i 98 (71.01%) 102 (76.69%) 0.248
Orlistat 35 (25.36%) 27 (20.30%) 0.338
Pioglitazone 49 (35.50%) 50 (37.59%) 0.688
Alpha-glucosidase inhibitors 21 (15.21%) 24 (8.04%) 0.532
Sulfonylureas 108 (78.26%) 111(83.45%) 0.231
Basal insulin 28 (20.28%) 37 (27.81%) 0.138
Short acting insulin 20 (14.49%) 22 (16.5%) 0.623
ACR [mg/gm] 63 [32.2–212] 72 [16–331] 0.483
Normality of the variable distribution calculated using Kolmogorov Smirov test; All normally distributed variables expressed as mean ± standard deviation; 
†all non-normally distributed variables expressed as median [25th–75th percentile]; discreet variables have been expressed as absolute numbers and percents; 
P < 0.05 considered statistically significant; D HbA1c: HbA1c at 6 months — HbA1c at baseline; GLP1a: glucagon like peptide receptor-1 antagonists; BMI: 
body mass index; DPP4i: dipeptidyl peptidase 4 inhibitor; SBP: systolic blood pressure; DBP: diastolic blood pressure; ACR: spot urine albumin creatinine 
ratio; LDL-C — low density lipoprotein cholesterol; HbA1c — glycated haemoglobin; *duration of diagnosis (in years) as told by the patient
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genital infection and one report of upper urinary tract 
infection involving the kidneys. There were no reports 
of fractures, amputations, euglycaemic ketosis or any 
hypersensitivity reactions. The occurrence of adverse 
drug reactions was comparable across the three dif-
ferent dose groups of canagliflozin (Table 1). Monthly 
cost of canagliflozin 100 mg/d, 150 mg/d and 300 mg/d 
was INR 1,635, INR 1,800 and INR 3,600, respectively.
Discussion
Literature is available to suggest that the function 
and efficacy of canagliflozin changes with increases in 
its doses. Polidori et al. [21] reported that the transient 
intestinal inhibition of SGLT1 was observed with cana-
gliflozin primarily at doses > 200 mg/day. Studies have 
also suggested that higher doses of canagliflozin have 
a more sustained 24-hour inhibition of renal glucose 
Table 3. Baseline clinical and treatment parameters and outcomes after 6 months of follow-up in patients receiving 
canagliflozin 100 mg per day as compared to those receiving 300 mg per day









Age (years) 54.26 ± 10.58 54.62 ± 10.08 0.771
Sex (Male: Female) 139: 118 71: 62 0.895
Duration of diagnosis (years)* 4.5 [2.0–8.0] 4.0 [2.07–7.0] 0.923
BMI [kg/m2] 27.96 ± 5.29 32.92 ± 5.78 < 0.001
SBP [mm Hg] 131.12 ± 19.7 135.89 ± 19.4 0.027
DBP [mm Hg] 79.19 ± 10.32 82.25 ± 10.4 0.007
Weight [kg]† 72.95 [65.08–82.38] 84.6 [76.6–95.5] < 0.001
Weight loss [kg]† –1.05 [–2.85 to –0.17] –3.0 [–5.3 to –0.8] < 0.001
Percent weight loss at 6 months (%)† –1.31 [–3.28 to –0.22] –3.33 [–6.00 to –0.99] 0.002
HbA1c (%) 8.1 [ 7.0–9.6] 8.8 [7.5–9.6] 0.983
[mmol/mol]† 65 [53–81] 73 [58–81]
HbA1c at 6 months (%) 7.70 [6.4–8.6] 7.2 [6.1–8.4] 0.576
[mmol/mol]† 61 [46–70] 55 [43–68]
D HbA1c (%)
† –0.75 [–2.25–0.15] –0.95 [–1.92 to –0.38] 0.627
HbA1c < 5.7% at 6 months 6 (2.33%) 6 (4.5%) 0.785
Creatinine [µmol/L] 78.68 ± 20.33 78.68 ± 30.94 0.953
Haemoglobin [gm/dL] 12.08 ± 1.91 12.51 ± 2.22 0.614
LDL-C [mmol/L]† 2.56 [1.74–3.42] 2.46 [2.06–3.45] 0.304
Triglycerides [mmol/L]† 1.93 [1.30–2.94] 2.31 [1.38–3.27] 0.629
Hypothyroidism 26 (10.11%) 11 (8.27%) 0.987
Metformin 229 (89.10%) 127 (95.48%) 0.054
GLP1a 28 (10.89%) 14 (10.52%) 0.911
DPP4i 195 (75.87%) 102 (76.69%) 0.858
Orlistat 45 (17.50%) 27 (20.30%) 0.501
Pioglitazone 112 (43.57%) 50 (37.59%) 0.255
Alpha-glucosidase inhibitors 29 (11.28%) 24 (8.04%) 0.067
Sulfonylureas 219 (85.21%) 111(83.45%) 0.649
Basal insulin 50 (19.45%) 37 (27.81%) 0.063
Short acting insulin 28 (10.89%) 22 (16.5%) .1170
ACR [mg/gm] 64 [32–187] 72 [16–331] 0.606
Normality of the variable distribution calculated using Kolmogorov Smirov test; All normally distributed variables expressed as mean ± standard deviation; 
†all non-normally distributed variables expressed as median [25th–75th percentile]; discreet variables have been expressed as absolute numbers and percents; 
P < 0.05 considered statistically significant; D HbA1c — HbA1c at 6 months–HbA1c at baseline; GLP1a — glucagon like peptide receptor-1 antagonists;  
BMI — body mass index; DPP4i — dipeptidyl peptidase 4 inhibitor; SBP — systolic blood pressure; DBP — diastolic blood pressure; ACR — spot urine albu-
min creatinine ratio; LDL-C — low density lipoprotein cholesterol; HbA1c — glycated haemoglobin; *duration of diagnosis (in years) as told by the patient
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resorption [22]. A head-to-head pharmacokinetic- 
-pharmacodynamic study of canagliflozin 300 mg versus 
dapagliflozin 10 mg demonstrated an additional about 
25% lowering of 2-hour prandial glucose with cana-
gliflozin [22, 23]. Phase III studies of CANA-300 have 
demonstrated an additional 5–20% patients achieving 
HbA1c < 7% over CANA-100 [23]. Also, CANA-300 was 
shown to have greater blood-pressure and body-weight 
lowering trends over CANA-100 in some of the study 
groups [23]. In a Bayesian network meta-analysis of 
13 trials, Shyangdan et al. [24] reported a statistically 
significant lowering of HbA1c with CANA-300 in mono-
therapy (D –0.2%; 95% confidence interval [CI] –0.05 
to –0.36) and dual therapy as add on to metformin 
(D –0.15%; 95% CI, –0.04 to –0.26), compared to 
CANA-100. In another larger network meta-analysis 
Table 4. Baseline clinical and treatment parameters and outcomes after 6 months of follow-up in patients receiving 
canagliflozin 100 mg per day as compared to those receiving 150 mg per day









Age (years) 54.26 ± 10.58 45.31 ± 13.86 < 0.001
Sex (Male: Female) 139: 118 78:61 0.699
Duration of diagnosis (years)* 4.5 [2.0–8.0] 4.0 [2.0–5.0] 0.133
BMI [kg/m2] 27.96 ± 5.29 34.95 ± 5.76 < 0.001
SBP [mm Hg] 131.12 ± 19.7 134.92 ± 21.3 0.096
DBP [mm Hg] 79.19 ± 10.32 84.05 ± 10.61 < 0.001
Weight [kg]† 72.95 [65.08–82.38] 93.9 [80.03–105.98] < 0.001
Weight loss [kg]† –1.05 [–2.85 to –0.17] –3.5 [–6.60–0.00] 0.002
Percent weight loss at 6 months (%)† –1.31 [–3.28 to –0.22] –3.62 [–6.64–0.00] 0.021
HbA1c (%) 8.1 [ 7.0–9.6] 8.1 [6.8–9.2] 0.118
[mmol/mol]† 65 [53–81] 65 [51–77] 0.071
HbA1c at 6 months (%) 7.70 [6.4–8.6] 7.0 [6.1–8.0]
[mmol/mol]† 61 [46–70] 53 [43–64]
D HbA1c (%)
† –0.75 [–2.25–0.15] –0.90 [–1.8 to –0.05] 0.990
HbA1c < 5.7% at 6 months 6 (2.33%) 14 (10.14%) 0.135
Creatinine [µmol/L] 78.68 ± 20.33 69.84 ± 0.22.10 0.060
Haemoglobin [gm/dL] 12.08 ± 1.91 13.23 ± 1.99 0.011
LDL-C [mmol/L]† 2.56 [1.74–3.42] 2.85 [2.01–3.94] 0.026
Triglycerides [mmol/L]† 1.93 [1.30–2.94] 1.81 [1.46–2.59] 0.310
Hypothyroidism 26 (10.11%) 30 (21.73%) 0.170
Metformin 229 (89.10%) 128 (92.75%) 0.342
GLP1a 28 (10.89%) 25 (18.11%) 0.063
DPP4i 195 (75.87%) 98 (71.01%) 0.245
Orlistat 45 (17.50%) 35 (25.36%) 0.323
Pioglitazone 112 (43.57%) 49 (35.50%) 0.107
Alpha-glucosidase inhibitors 29 (11.28%) 21 (15.21%) 0.269
Sulfonylureas 219 (85.21%) 108 (78.26%) 0.060
Basal insulin 50 (19.45%) 28 (20.28%) 0.884
Short acting insulin 28 (10.89%) 20 (14.49%) 0.316
ACR [mg/gm] 64 [32–187] 63 [32.2–212] 0.132
Normality of the variable distribution calculated using Kolmogorov Smirov test; All normally distributed variables expressed as mean ± standard deviation; 
†all non-normally distributed variables expressed as median [25th–75th percentile]; discreet variables have been expressed as absolute numbers and percents; 
P < 0.05 considered statistically significant; D HbA1c — HbA1c at 6 months–HbA1c at baseline; GLP1a — glucagon like peptide receptor-1 antagonists;  
BMI — body mass index; DPP4i — dipeptidyl peptidase 4 inhibitor; SBP — systolic blood pressure; DBP — diastolic blood pressure; ACR — spot urine albu-
min creatinine ratio; LDL-C — low density lipoprotein cholesterol; HbA1c — glycated haemoglobin; 
*duration of diagnosis (in years) as told by the patient
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Table 5. Baseline clinical and treatment parameters and outcomes after 6 months of follow-up in patients receiving 
canagliflozin 100 mg per day as compared to those receiving 150 mg or 300 mg per day







150 mg/d or 300 mg/d 
n = 271
Age (years) 54.26 ± 10.58 49.89 ± 13.00 < 0.001
Sex (Male:Female) 139: 118 149:123 0.873
Duration of diagnosis (years)* 4.5 [2.0–8.0] 4.0 [2.0–6.0] 0.381
BMI [kg/m2] 27.96 ± 5.29 33.91 ± 5.84 < 0.001
SBP [mm Hg] 131.12 ± 19.7 135.4 ± 20.3 0.018
DBP [mm Hg] 79.19 ± 10.32 83.11 ± 10.52 < 0.001
Weight [kg]† 72.95 [65.08–82.38] 89.95 [79.5–100.07] < 0.001
Weight loss [kg]† –1.05 [–2.85 to –0.17] –3.0 [–5.60 to –0.60] < 0.001
Percent weight loss at 6 months (%)† –1.31 [–3.28 to –0.22] –3.39 [–6.34 to –0.71] 0.004
HbA1c (%) 8.1 [ 7.0–9.6] 8.4 [6.7–9.4] 0.242
[mmol/mol]† 65 [53–81] 68 [50–79]
HbA1c at 6 months (%) 7.70 [6.4–8.6] 7.1 [6.1–8.0] 0.230
[mmol/mol]† 61 [46–70] 54 [43–64]
D HbA1c (%)
† –0.75 [–2.25–0.15] –0.9 [–1.9 to –0.3] 0.769
HbA1c < 5.7% at 6 months 6 (2.33%) 20 (7.38%) 0.429
Creatinine [µmol/L] 78.68 ± 20.33 74.26 ± 26.52 0.258
Haemoglobin [gm/dL] 12.08 ± 1.91 12.86 ± 2.3 0.069
LDL-C [mmol/L]† 2.56 [1.74–3.42] 2.67 [2.05–3.73] 0.101
Triglycerides [mmol/L]† 1.93 [1.30–2.94] 178 [129–249.5] 0.756
Hypothyroidism 26 (10.11%) 41 (15.12%) 0.313
Metformin 229 (89.10%) 255 (94.09%) 0.079
GLP1a 28 (10.89%) 39 (14.39%) 0.234
DPP4i 195 (75.87%) 200 (73.8%) 0.535
Orlistat 45 (17.50%) 57 (21.031%) 0.186
Pioglitazone 112 (43.57%) 99 (36.53%) 0.098
Alpha-glucosidase inhibitors 29 (11.28%) 45 (16.61%) 0.081
Sulfonylureas 219 (85.21%) 219 (80.81%) 0.152
Basal insulin 50 (19.45%) 65 (23.98%) 0.224
Short acting insulin 28 (10.89%) 42 (15.49%) 0.127
ACR [mg/gm] 64 [32–187] 64 [32–415] 0.204
Normality of the variable distribution calculated using Kolmogorov Smirov test; All normally distributed variables expressed as mean ± standard deviation; 
†all non–normally distributed variables expressed as median [25th–75th percentile]; discreet variables have been expressed as absolute numbers and per-
cents; P < 0.05 considered statistically significant; D HbA1c — HbA1c at 6 months–HbA1c at baseline; GLP1a — glucagon like peptide receptor-1 antagonists; 
BMI — body mass index; DPP4i — dipeptidyl peptidase 4 inhibitor; SBP — systolic blood pressure; DBP — diastolic blood pressure; ACR — spot urine albu-
min creatinine ratio; LDL-C — low density lipoprotein cholesterol; HbA1c — glycated haemoglobin; 
*duration of diagnosis (in years) as told by the patient
of 38 trials involving 23,997 patients, a statistically 
significant reduction of HbA1c (D –0.1%; 95% CI, 0.00 
to –0.20), fasting glucose (D –0.33 mmol/L; 95% CI, 
–0.07 to –0.90), body weight (D –0.61 kg; 95% CI, 
–0.23 to –0.99) and SBP (D –0.98 mm Hg; 95% CI, 0.00 
to –1.96) was noted with CANA-300 as compared to 
CANA-100 [25].
Although there are no head-to-head comparison 
studies on the efficacy of different SGLT2 inhibitors, 
Singh et al. [23], through indirect comparison of re-
sults of different clinical trials, noted that canagliflozin 
300 mg gave the highest reduction in HbA1c (either 
monotherapy or as a part of multidrug therapy), not-
ing an additional HbA1c lowering of 0.11–0.33%, in 
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the background of similar baseline HbA1c and duration 
of the studies. With regards to weight loss, weight 
reduction appeared larger with CANA-300 in clinical 
trials, except when CANA-300 was a part of triple-
drug therapy with sulfonylureas and metformin [23]. 
However, baseline body weights were also different 
to start with in these patients [23]. In the Bayesian 
network meta-analysis from 13 trials by Shyangdan 
et al. (vide supra) CANA-300 was shown to have 
a greater glycaemic efficacy than other SGLT2 inhibi-
tors as monotherapy (additional HbA1c reduction of 
D –0.37%; 95% CI –0.16 to –0.58 w.r.t empagliflozin 
25 mg/day and D –0.64%; 95% CI –0.45 to –0.83 with 
regards to dapagliflozin 10 mg/day) [24]. With regards 
to weight reduction CANA-300 was associated with 
a statistically significant reduction of weight as com-
pared to empagliflozin 10 mg/day [24]. These results 
were replicated in a network meta-analysis by Zaccardi 
et al. (vide supra) [25]. CANA-300 was associated with 
an additional 0.21% and 0.20% lowering of HbA1c w.r.t 
dapagliflozin 10 mg/day and empagliflozin 25 mg/day, 
respectively, without any statistically significant differ-
ence in body weight reduction. The differences were 
blunted when SGLT2 inhibitors were used as a part of 
dual- or multi-drug therapy [23–25]. Hence, preclinical 
data as well as data from clinical trials suggest that 
not only canagliflozin may be the most potent SGLT2 
inhibitor, because of its additional SGLT1 inhibiting 
properties, but also that higher doses of canagliflozin 
may have increased therapeutic benefits.
Our study demonstrated, for the first time in 
a real-world setting, that higher doses of canagliflozin, 
150 mg/day and 300 mg/day, were superior in terms 
of causing both absolute and percent weight loss as 
compared to canagliflozin 100 mg/day when used as 
a part of standard of care for managing diabesity. The 
highlight of this study is the comparable use of all the 
different anti-diabetes medications across all the three 
study groups, especially medications which are linked 
with mild weight gain like sulfonylureas, pioglitazone 
and insulin, thus negating any potential impact of these 
medications on the study outcomes (glycaemic efficacy 
and weight loss). 
It is important to highlight here that the differences 
in the baseline BMI may have impacted the absolute 
weight loss, but has no impact on percent weight loss. 
Following 6 months of treatment, the absolute weight 
loss was significantly higher in patients receiving cana-
gliflozin 150 mg/day as compared to those receiving 
100 mg/day and 300 mg/day (P = 0.002) (Table 1). The 
highest baseline BMI in canagliflozin 150 mg/d group 
may have contributed to the greater absolute weight 
loss in that group. However, it must be realised that the 
percent weight loss after 6 months of therapy (which 
is not effected by the higher baseline BMI) was also 
significantly higher in canagliflozin 150 mg/d group 
as compared to canagliflozin 300 mg/d and canagli-
flozin 100 mg/d group (P = 0.014). Post-hoc analysis 
confirmed that in terms of both absolute and percent 
weight loss, canagliflozin 150 mg/day and 300 mg/day 
performed similarly. 
The glycaemic efficacy was comparable across 
the three different doses of canagliflozin used in this 
study. Since canagliflozin was used as a part of multi 
drug therapy in this real-world study, this may explain 
the lack of difference in HbA1c reduction across the 
different doses of canagliflozin. This study provided 
reassuring data, for the first time, that the glycaemic 
and the weight-loss benefits of CANA-300 tablet is 
retained, even when it is broken into half and taken 
over 2 different days. “Tablet splitting” not something 
new, and has been in practice for a long time in India, 
USA and many other countries across the globe. Free-
man et al in a review of PubMed (1966–June 2011) 
and International Pharmaceutical Abstract (1975–June 
2011) found 17 studies dealing with different clinical 
outcomes, patient acceptance or economic benefits of 
“tablet splitting” [26]. Patients with chronic disorders, 
which often needed life-long therapy were most com-
monly doing “tablet-splitting” viz those on statins, 
anti-hypertensive medications and anti-psychotics. 
Their main conclusion was “tablet splitting” did not 
seem to effect clinical outcomes related to hyperten-
sion, cholesterol, or psychiatric disorders [26]. The 
authors’ personal observation are that tablet splitting 
is commonly practiced in India with regards to diabe-
tes medications, as especially with relatively costlier 
medications like SGLT2 inhibitors. 
Canagliflozin 150 mg/day (half tablet of CANA-
-300) is significantly cheaper, having a monthly cost 
of therapy INR 1,800, as compared to INR 3,600 for 
CANA-300 [13, 14]. The monthly cost of canagliflozin 
150 mg/day is only marginally higher than canagliflozin 
100 mg/day (INR 1,800 versus INR 1,635, respectively) 
[13, 14], but the therapeutic benefits of canagliflozin 
150 mg/day is superior to 100 mg/day. 
The limitations of this study include the lack of 
matching of study groups at baseline, especially with 
regards to age and body weight. These are limitations 
intrinsic to real-world studies, where matching and 
randomisation is not possible. Hence, we have focussed 
on percent weight loss and not absolute weight loss, 
which would not be affected by the baseline weight/ 
/BMI. Other limitations include the short study period 
of 6 months, making it difficult to assess long-term 
weight loss, and the lack of robust data on adherence. 
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However, as a department policy we always encourage 
our patients to carry medicines with them whenever 
they come for visits to the outpatient department (for 
checking and verification), and collect back empty packs 
of medicines from patients during these follow-up visits 
to ensure a good compliance of medication intake. This 
study highlights the significant cost benefits of using 
half tablet of CANA-300 in clinical practice, without 
any compromise in the glycaemic efficacy and weight 
loss properties of this molecule.
To summarise, this is the first study, to date, that 
documents the glycaemic efficacy, durability and 
weight-loss potential of half tablet of CANA-300 taken 
once a day over a period of 6 months. Half tablet of 
CANA-300 (150 mg/day) is associated with a signifi-
cantly greater weight loss and comparable glycaemic 
efficacy as compared to 1 tablet of CANA-100 with 
similar costing. Half tablet of CANA-300 (150 mg/day) 
has glycaemic and weight-loss efficacy equivalent to 
that of 1 tablet of CANA-300 when used as a part of 
multi-drug therapy for managing diabesity in India. 
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